5AM Partners VII, LLC sold $801k of SKYE
owner at Skye Bioscience, Inc.. 231,405 shares at an average of $3.46, traded Aug 21, 2025, filed Aug 22, 2025.
Score components
- +12Role10% owner
- +22Trade size$801k at market
- +5Share of holdings soldSold 14% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-022806, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 21, 2025 | SOpen-market sale Common Stockindirect: By 5AM Ventures II, L.P. | -58,642 | $3.57 | $209k | 1,621,043 | Aug 22, 2025 |
| Aug 21, 2025 | SOpen-market sale Common Stockindirect: By 5AM Co-Investors II, L.P. | -2,314 | $3.57 | $8,261 | 63,963 | Aug 22, 2025 |
| Aug 22, 2025 | SOpen-market sale Common Stockindirect: By 5AM Ventures II, L.P. | -163,979 | $3.42 | $561k | 1,457,064 | Aug 22, 2025 |
| Aug 22, 2025 | SOpen-market sale Common Stockindirect: By 5AM Co-Investors II, L.P. | -6,470 | $3.42 | $22k | 57,493 | Aug 22, 2025 |
Related signals
Other insiders at Skye Bioscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $240k 148,079 shares | -104% | |
| 56Moderate | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $240k 148,079 shares | -104% | |
| 33Weak | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $65k 33,892 shares | -19% | |
| 36Weak | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $65k 33,892 shares | -19% | |
| 50Moderate | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $801k 231,405 shares | -14% | |
| 45Moderate | Skye Bioscience, Inc. | Tuan Tu Diep Chief Development Officer | $98k 19,574 shares | -19% | |
| 54Moderate | Skye Bioscience, Inc. | Kaitlyn Arsenault Chief Financial Officer | $217k 43,396 shares | -21% | |
| 61Notable | Skye Bioscience, Inc. | Punit Dhillon Chief Executive Officer | $414k 82,910 shares | -20% | |
| 52Moderate | Skye Bioscience, Inc. | Paul A. Grayson director | $432k 86,551 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.